Bio-Thera Solutions (688177.SH) announced a net loss attributable to the parent company of 510 million yuan for the year 2024.

Bio-Thera Solutions (688177.SH) released its annual report for 2024, with the company's operating income reaching 743 million yuan, a year-on-year growth of 5.44%. The net loss attributable to shareholders of the listed company was 510 million yuan, with an increase compared to the previous year. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 556 million yuan. The basic loss per share was 1.23 yuan. During the reporting period, Gelexi (adalimumab injection) continued to grow, and at the same time, overseas supply operations for tocilizumab injection were introduced. However, overseas partners are still in the early stages of expansion, resulting in a relatively small overall increase in operating income.